Rituximab

This month’s cover story features an illustrious faculty — Christina Charles-Schoeman, MD, MS; Kathryn Dao, MD; Roy Fleischmann, MD; Jon T. Giles, MD, MPH; and Grace C. Wright, MD, PhD — and highlights the evolution of safety in our field, a phenomenon profoundly influenced by our rich armamentarium of targeted therapies not even dreamed of when I started training.

Data from U.S. and European COVID-19 registries of patients with rheumatic diseases have yielded actionable information to help rheumatologists manage patients with the virus, according to data presented at EULAR 2022 Congress.

The FDA has approved rituximab-arrx, in combination with methotrexate, in adult patients with moderate or severely active rheumatoid arthritis who have had inadequate responses to one or more TNF agonist therapies.

The FDA has approved rituximab-arrx, in combination with methotrexate, in adult patients with moderate or severely active rheumatoid arthritis who have had inadequate responses to one or more TNF agonist therapies.

CHICAGO — A novel first-line regimen significantly improved PFS compared with standard chemoimmunotherapy for older patients with mantle cell lymphoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.

DESTIN, Fla. — Adjustments made to the dosing and administration of immunomodulatory drugs may not have much impact on COVID-19 vaccine immunogenicity among patients with autoimmune and inflammatory rheumatic disease, according to data.

Rituximab-treated patients with MS may be vaccinated for COVID-19 as soon as possible, researchers reported in JAMA Network Open.

Worse COVID-19 outcomes in patients with systemic lupus erythematosus are driven by comorbidities, demographics and untreated or active disease, according to data published in the Annals of the Rheumatic Diseases.

In this video, Allyson Pishko, MD, MSCE, discussed the results of the CADENZA study presented at ASH Annual Meeting and Exposition.

There are no clinically relevant differences in treatment retention among patients receiving biosimilar or originator biologic disease-modifying antirheumatic drugs as first exposure to that drug, data published in Rheumatology show.